Developer docs
API playgroundTry for free, no card

Search company profiles

Stellar Biotechnologies

Full company profile

uuid000614p

Namestring
Stellar Biotechnologies
Legal namestring
扬州市职业大学
Websiteurl
stellarklh.com
Company typeenum
Private
Founded yearint
1917
Descriptiontext

Stellar Biotechnologies is a small United States-based biotechnology company founded in 1999 and historically headquartered in Port Hueneme CBC Base, California. The company was built around a proprietary Keyhole Limpet Hemocyanin (KLH) protein technology platform, used as a carrier and immune-stimulating adjuvant in conjugate vaccines and immunotherapy candidates, with stated therapeutic focus areas in dermatological and anorectal diseases. The firm was publicly traded on NASDAQ under the ticker SBOT but is currently delisted, and now operates with a reported headcount band of 11-50 employees.

Across its operating life, Stellar raised approximately $46.7 million across nine disclosed funding rounds between 2010 and 2021, with the most recent round in March 2021 raising approximately $10 million. The only round with named institutional investors was the September 2017 financing of approximately $7 million, led by Lumira Ventures with participation from Inveready and Pharmascience. Leadership currently comprises Frank Oakes as President & CEO, Kathi Niffenegger as CFO and Corporate Secretary, and Daniel E. Morse as a director — a reduced team for a publicly-traded biotech.

The current operating posture is materially weakened relative to historical norms. The firm's primary web domain (stellarklh.com) no longer hosts Stellar Biotechnologies content and instead resolves to unrelated Chinese vocational-education material, indicating the digital infrastructure is no longer being maintained by the issuer. No product launches, partnerships, M&A, or additional capital raises are documented post-March 2021, and the company has not sought to re-list. Taken together, these signals suggest Stellar is either in a state of operational dormancy, an orderly wind-down, or a skeleton-staffed legacy operation retaining residual licensing or supply arrangements — the data does not support characterization of an actively growing enterprise.

Short descriptiontext

Stellar Biotechnologies is a delisted US biotech founded in 1999 that built a proprietary Keyhole Limpet Hemocyanin (KLH) protein platform for immunotherapy and conjugate-vaccine applications, focused historically on dermatological and anorectal disease treatments; the firm now appears operationally dormant.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLos Angeles, United States
HQ citystring
Los Angeles
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
biopharmaceutical development, dermatological therapeutics, anorectal treatments, clinical-stage biotechnology, protein therapeutics
Industry2 codes
PRIMARYHLAIACAL
Dermatology Specialty Pharmaceuticals
SECONDARYCRABAAAF
Dermocosmetics & Medical-Grade Skincare
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals
No data
Cost components4 values
Technology or R&D, Personnel, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1医学院 (Medical College)
Description

Medical department of Yangzhou Vocational University

Core offering1 text field

Stellar Biotechnologies develops treatments for dermatological and anorectal diseases. The company operates as a clinical-stage biotechnology developer focused on therapeutic candidates targeting these specialty disease areas. Its work centers on the research and development of biopharmaceutical treatment candidates.

Differentiator
Functional benefit
Problem solved
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialty pharmaceutical company with a portfolio in dermatology and other niche therapeutic areas; comparable as a small-cap specialty-pharma operator with dermatology focus.

TypeDirect peer
Description

Specialty dermatology biotech developing innovative topical treatments for inflammatory skin conditions; comparable as a focused, clinical-stage developer in dermatology.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company focused on dermatology and immunology; comparable as a focused developer in inflammatory skin conditions.

TypeDirect peer
Description

Specialty dermatology company developing topical branded generics and innovative therapies for skin diseases; comparable as a small-cap dermatology developer.

TypeBroad incumbent
Description

Large specialty pharma with a meaningful dermatology franchise (including anorectal treatments such as Rectiv); comparable as a broad incumbent with overlap in dermatology and anorectal indications.

TypeDirect peer
Description

Dermatology-focused biopharmaceutical company developing therapies for skin diseases; directly comparable in therapeutic focus and small-cap development model.

TypeBroad incumbent
Description

Global dermatology-focused pharmaceutical company with broad prescription, aesthetic, and consumer skincare portfolios; comparable as a scaled dermatology player and likely acquirer of niche developers.

TypeBroad incumbent
Description

Large pharmaceutical company that acquired Anacor to gain dermatology assets (e.g., crisaborole); comparable as a dermatology platform acquirer and benchmark for specialty-pharma exit outcomes.

TypeBroad incumbent
Description

Global specialty pharmaceutical company focused on dermatology; comparable as a mid-sized dermatology incumbent with active licensing and M&A activity.

TypeDirect peer
Description

Specialty pharma developing topical therapeutics for skin diseases including dermatologic oncology; comparable as a small-cap, dermatology-focused developer.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

No data
Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Stellar Biotechnologies

Biopharmaceuticalsstellarklh.com

Stellar Biotechnologies is a delisted US biotech founded in 1999 that built a proprietary Keyhole Limpet Hemocyanin (KLH) protein platform for immunotherapy and conjugate-vaccine applications, focused historically on dermatological and anorectal disease treatments; the firm now appears operationally dormant.

What Stellar Biotechnologies does

Stellar Biotechnologies is a small United States-based biotechnology company founded in 1999 and historically headquartered in Port Hueneme CBC Base, California. The company was built around a proprietary Keyhole Limpet Hemocyanin (KLH) protein technology platform, used as a carrier and immune-stimulating adjuvant in conjugate vaccines and immunotherapy candidates, with stated therapeutic focus areas in dermatological and anorectal diseases. The firm was publicly traded on NASDAQ under the ticker SBOT but is currently delisted, and now operates with a reported headcount band of 11-50 employees.

Across its operating life, Stellar raised approximately $46.7 million across nine disclosed funding rounds between 2010 and 2021, with the most recent round in March 2021 raising approximately $10 million. The only round with named institutional investors was the September 2017 financing of approximately $7 million, led by Lumira Ventures with participation from Inveready and Pharmascience. Leadership currently comprises Frank Oakes as President & CEO, Kathi Niffenegger as CFO and Corporate Secretary, and Daniel E. Morse as a director — a reduced team for a publicly-traded biotech.

The current operating posture is materially weakened relative to historical norms. The firm's primary web domain (stellarklh.com) no longer hosts Stellar Biotechnologies content and instead resolves to unrelated Chinese vocational-education material, indicating the digital infrastructure is no longer being maintained by the issuer. No product launches, partnerships, M&A, or additional capital raises are documented post-March 2021, and the company has not sought to re-list. Taken together, these signals suggest Stellar is either in a state of operational dormancy, an orderly wind-down, or a skeleton-staffed legacy operation retaining residual licensing or supply arrangements — the data does not support characterization of an actively growing enterprise.

Stellar Biotechnologies firmographics

Firmographics
Name
Stellar Biotechnologies
Legal name
扬州市职业大学
Website
https://stellarklh.com
Company type
Private
Founded year
1917
Operating status
Operating
Headcount range
1–10 employees
Short description
Stellar Biotechnologies is a delisted US biotech founded in 1999 that built a proprietary Keyhole Limpet Hemocyanin (KLH) protein platform for immunotherapy and conjugate-vaccine applications, focused historically on dermatological and anorectal disease treatments; the firm now appears operationally dormant.
Ownership category
akta.pro rank

Stellar Biotechnologies industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAL
Dermatology Specialty Pharmaceuticals
SECONDARYCRABAAAF
Dermocosmetics & Medical-Grade Skincare

Keywords

  • Biopharmaceutical development
  • Dermatological therapeutics
  • Anorectal treatments
  • Clinical-stage biotechnology
  • Protein therapeutics

Where Stellar Biotechnologies is headquartered

Location

Headquarters

HQ city
Los Angeles
HQ country
United States
HQ region
North America

Markets served

Stellar Biotechnologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure

Stellar Biotechnologies product offering

Product offering

Core offering

Stellar Biotechnologies develops treatments for dermatological and anorectal diseases. The company operates as a clinical-stage biotechnology developer focused on therapeutic candidates targeting these specialty disease areas. Its work centers on the research and development of biopharmaceutical treatment candidates.

Differentiator

Problem solved

Functional benefit

Brands

  • 医学院 (Medical College): Medical department of Yangzhou Vocational University

Stellar Biotechnologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Stellar Biotechnologies partnerships and signals

Strategic signal

Recent moves5 records

Expansion highlights3 records

Stellar Biotechnologies competitors and assessment

Company assessment

Direct peers

  • Cipher Pharmaceuticals: Specialty pharmaceutical company with a portfolio in dermatology and other niche therapeutic areas; comparable as a small-cap specialty-pharma operator with dermatology focus.
  • Arcutis Biotherapeutics: Specialty dermatology biotech developing innovative topical treatments for inflammatory skin conditions; comparable as a focused, clinical-stage developer in dermatology.
  • Aclaris Therapeutics: Clinical-stage biopharmaceutical company focused on dermatology and immunology; comparable as a focused developer in inflammatory skin conditions.
  • Sol-Gel Technologies: Specialty dermatology company developing topical branded generics and innovative therapies for skin diseases; comparable as a small-cap dermatology developer.
  • Dermavant Sciences: Dermatology-focused biopharmaceutical company developing therapies for skin diseases; directly comparable in therapeutic focus and small-cap development model.
  • Verrica Pharmaceuticals: Specialty pharma developing topical therapeutics for skin diseases including dermatologic oncology; comparable as a small-cap, dermatology-focused developer.

Broad incumbents

  • Bausch Health: Large specialty pharma with a meaningful dermatology franchise (including anorectal treatments such as Rectiv); comparable as a broad incumbent with overlap in dermatology and anorectal indications.
  • Galderma: Global dermatology-focused pharmaceutical company with broad prescription, aesthetic, and consumer skincare portfolios; comparable as a scaled dermatology player and likely acquirer of niche developers.
  • Pfizer (Anacor): Large pharmaceutical company that acquired Anacor to gain dermatology assets (e.g., crisaborole); comparable as a dermatology platform acquirer and benchmark for specialty-pharma exit outcomes.
  • Almirall: Global specialty pharmaceutical company focused on dermatology; comparable as a mid-sized dermatology incumbent with active licensing and M&A activity.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks4 records

Key highlights4 records

Customer concentration

Stellar Biotechnologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Stellar Biotechnologies leadership team

Management profile

Number of profiles

Profiles3 records

Stellar Biotechnologies funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Stellar Biotechnologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stellar Biotechnologies

What does Stellar Biotechnologies do?

Stellar Biotechnologies develops treatments for dermatological and anorectal diseases. The company operates as a clinical-stage biotechnology developer focused on therapeutic candidates targeting these specialty disease areas. Its work centers on the research and development of biopharmaceutical treatment candidates.

Is Stellar Biotechnologies a public or private company?

Stellar Biotechnologies is a private company. It is classified as unknown and is currently operating.

When was Stellar Biotechnologies founded?

Stellar Biotechnologies was founded in 1917. It employs 1 to 10 people.

Where is Stellar Biotechnologies based?

Stellar Biotechnologies is headquartered in Los Angeles, United States, in the North America region.

Who are Stellar Biotechnologies's main competitors?

Direct peers on record are Cipher Pharmaceuticals, Arcutis Biotherapeutics, Aclaris Therapeutics, Sol-Gel Technologies, Dermavant Sciences and Verrica Pharmaceuticals. Broad incumbents are Bausch Health, Galderma, Pfizer (Anacor) and Almirall.

Does Stellar Biotechnologies have an API?

No public API is recorded for Stellar Biotechnologies.

What industry is Stellar Biotechnologies in?

Stellar Biotechnologies's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAL, Dermatology Specialty Pharmaceuticals, with a secondary code of CRABAAAF, Dermocosmetics & Medical-Grade Skincare. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioWorldEdesa’s COVID-19 IND sparks the stockEdesa Biotech filed an IND with the FDA to start a phase II/III study of its monoclonal antibody EB-05 for COVID-19. The filing sent the company's stock up 81.38% to $9.45, trading as high as $19.10. The drug targets TLR4 signaling, joining a small group of COVID-19 treatments in that class.PR NewswireThinking about buying stock in Aurora Cannabis, Cypress Semiconductor, Delmar Pharmaceuticals, Genocea Biosciences, or Stellar Biotech?InvestorsObserver issued critical PriceWatch Alerts for Aurora Cannabis, Cypress Semiconductor, Delmar Pharmaceuticals, Genocea Biosciences, and Stellar Biotech. The alerts are based on a proprietary scoring methodology that evaluates short-term technical, long-term technical, and fundamental factors to determine investment suitability.BenzingaWhy Stellar Biotech Shares Are Up 70%Stellar Biotech shares rose over 70% after an 8-K filing disclosed a share exchange agreement with Edesa Biotech. Under the deal, Edesa shareholders exchanged their shares for newly-issued Stellar common shares. The stock traded around $2.05, up 70.8%.PR NewswireStellar Biotechnologies Reports Second Quarter Financial ResultsStellar Biotechnologies reported second quarter fiscal 2019 financial results, including total revenues of $0.12 million and a net loss of $1.66 million, compared to a net loss of $1.35 million in the same period last year. The company announced it entered into a share exchange agreement with Canadian biopharmaceutical company Edesa Biotech Inc., a transaction expected to close in June 2019 that would result in a change in control of Stellar and transform it into a clinical-stage drug developer. Management stated it is conserving cash resources in light of the proposed transaction, with general and administrative expenses increasing by $0.56 million primarily due to legal and professional fees associated with the deal.socaltech.comStellar Biotechnologies Merges With Edesa BiotechStellar Biotechnologies completed a share exchange with Edesa Biotech, making Edesa a wholly-owned subsidiary. The companies will rename the combined entity as Edesa Biotech. Financial details of the deal were not disclosed.PR NewswireStellar Biotechnologies and Edesa Biotech Sign Share Exchange AgreementStellar Biotechnologies has executed a share exchange agreement to acquire privately-held Edesa Biotech, making Edesa a wholly-owned subsidiary in a transaction that will result in a change of control. Following the closing expected in Q2 2019, Edesa shareholders will own approximately 90% of the combined company while Stellar shareholders retain roughly 10%, subject to adjustments based on Stellar's working capital. Stellar will subsequently change its name to "Edesa Biotech Inc." and plans to wind down or spin off its legacy KLH protein manufacturing business.PR NewswireStellar Biotechnologies Reports First Quarter Financial ResultsStellar Biotechnologies reported its first quarter fiscal year 2019 financial results for the three months ended December 31, 2018, with total revenues increasing to $53,033 from $20,487 in the prior year period. The company reported a net loss of $1.41 million ($0.26 per basic share), essentially flat compared to the $1.40 million loss in the same period last year, while operating expenses increased slightly to $1.46 million. The company ended the quarter with approximately $8.96 million in cash and short-term investments, with management stating it is taking steps to conserve working capital and improve production efficiency.PR NewswireStellar Biotechnologies Reports Fiscal Year 2018 Financial ResultsStellar Biotechnologies reported financial results for fiscal year 2018 ended September 30, with total revenues of $0.21 million compared to $0.23 million the prior year, representing a slight decline due to decreased contract services revenue. The company posted a net loss of $5.04 million, essentially flat versus the $5.03 million loss in fiscal 2017, while raising approximately $8.8 million in net cash proceeds from equity financings and warrant exercises. Stellar ended the fiscal year with $10.3 million in cash and short-term investments, and announced infrastructure investments to expand aquaculture production capacity for its KLH products.GlobeNewswireDetailed Research: Economic Perspectives on Stellar Biotechnologies, MAM Software Group, EverQuote, Brainstorm Cell Therapeutics, Mid-Con Energy Partners, LP, and Staffing 360 Solutions — What DrivesMarket Source Research released independent research reports on Stellar Biotechnologies, MAM Software Group, EverQuote, Brainstorm Cell Therapeutics, Mid-Con Energy Partners, and Staffing 360 Solutions. The reports detail revenue and earnings per share figures for each company, along with analyst forecasts for upcoming earnings releases.PR NewswireStellar Biotechnologies to Present at BlueTech SummitStellar Biotechnologies, Inc. announced that President and CEO Frank R. Oakes will present at the 10th Annual BlueTech Summit in San Diego, California on November 7, 2018, participating in the Biomedicines panel discussion. The company is a manufacturer of Keyhole Limpet Hemocyanin (KLH), an immune-stimulating protein used as a carrier molecule in therapeutic vaccine pipelines targeting cancers, immune disorders, Alzheimer's, and inflammatory diseases. The conference, focused on sustainable ocean and water technologies, is presented by The Maritime Alliance.